Clinical characteristics of apixaban prescription in AF patients with single dose-reduction criterion: the ASPIRE (efficAcy and safety of aPixaban in rEal-world practice …
JM Choi, SR Lee, S Kwon, HJ Ahn, KY Lee… - Frontiers in …, 2024 - frontiersin.org
Background Data on off-label reduced dose risk among patients with atrial fibrillation (AF)
who qualify for a single-dose reduction of apixaban is scarce. Objectives We prospectively …
who qualify for a single-dose reduction of apixaban is scarce. Objectives We prospectively …
[HTML][HTML] Comparison of clinical effects and costs among dabigatran etexilate, rivaroxaban and warfarin in elderly patients with atrial fibrillation
J Di, Y Wei, G Zhang, Y Yue, S Sun - American Journal of …, 2023 - ncbi.nlm.nih.gov
Objective: To analyze the clinical effects and economic costs between Warfarin and novel
oral anticoagulants in elderly patients with atrial fibrillation (AF). Methods: This is a …
oral anticoagulants in elderly patients with atrial fibrillation (AF). Methods: This is a …
[HTML][HTML] Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide …
Venous thromboembolism (VTE) is associated with a high risk of morbidity and mortality.
However, data on the association between oral anticoagulants and the hazards of VTE …
However, data on the association between oral anticoagulants and the hazards of VTE …
Real‐World Comparisons of Low‐Dose NOACs versus Standard‐Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta‐Analysis
Z Li, X Wang, D Li, A Wen - Cardiology Research and Practice, 2022 - Wiley Online Library
Objective. We aimed to further investigate the efficacy and safety of low‐dose NOACs by
performing a meta‐analysis of cohort studies. Background. Meta‐analyses of randomized …
performing a meta‐analysis of cohort studies. Background. Meta‐analyses of randomized …
Differences in safety and efficacy of oral anticoagulants in patients with non‐valvular atrial fibrillation: A Bayesian analysis
Z Sun, Y Liu, Y Zhang, X Guo… - International Journal of …, 2019 - Wiley Online Library
Background Novel oral anticoagulants are the cornerstone of therapy for non‐valvular atrial
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …
[HTML][HTML] Long-term stroke and major bleeding risk in patients with non-valvular atrial fibrillation: A comparative analysis between non-vitamin K antagonist oral …
H Lee, JH Hong, KD Seo - Frontiers in Neurology, 2023 - frontiersin.org
Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) has been the drug of
choice for preventing ischemic stroke in patients with atrial fibrillation (AF) since 2014. Many …
choice for preventing ischemic stroke in patients with atrial fibrillation (AF) since 2014. Many …
Efficacy and safety of clinically driven low-dose treatment with direct Oral anticoagulants in Asians with atrial fibrillation: a systematic review and Meta-analysis
J Choi, JE No, JY Lee, SA Choi, WY Chung… - … Drugs and Therapy, 2022 - Springer
Purpose Although clinically driven low-dose (CDLD) treatment with direct oral
anticoagulants (DOACs) is frequently administered to Asian patients with atrial fibrillation …
anticoagulants (DOACs) is frequently administered to Asian patients with atrial fibrillation …
[HTML][HTML] Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
Background No real‐world data exist on outcomes in patients on anticoagulants and
concomitant antiarrhythmic medications. This study aims to compare the safety and …
concomitant antiarrhythmic medications. This study aims to compare the safety and …
Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis
X Wang, L Fang, B Liu, Y Zheng, J Zeng - Heart Failure Reviews, 2020 - Springer
We performed this meta-analysis to compare the efficacy and safety of reduced-dose non-
vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial …
vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial …
Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a …
EM Bunge, B van Hout, S Haas, G Spentzouris… - BMJ open, 2021 - bmjopen.bmj.com
Objective To critically appraise the published comparative effectiveness studies on non-
vitamin K antagonist oral anticoagulants (NOACs) in non-valvular atrial fibrillation (NVAF) …
vitamin K antagonist oral anticoagulants (NOACs) in non-valvular atrial fibrillation (NVAF) …